A5079451746- Breast Cancer Treatment Studies
- Colorectal Cancer Surgical Treatments
- Breast Lesions and Carcinomas
- Colorectal and Anal Carcinomas
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Global Cancer Incidence and Screening
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Colorectal Cancer Screening and Detection
- Breast Implant and Reconstruction
- Cancer Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Multiple and Secondary Primary Cancers
- Medical Imaging Techniques and Applications
- Estrogen and related hormone effects
- Economic and Financial Impacts of Cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Advanced Radiotherapy Techniques
- Cancer Risks and Factors
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Advances in Oncology and Radiotherapy
- Cancer Genomics and Diagnostics
BC Cancer Agency
2014-2023
Spinal Cord Injury BC
2023
University of British Columbia
2010-2020
University of Michigan
2017
Vancouver General Hospital
2006-2012
Breast Cancer Care
2006-2011
University of North Carolina at Chapel Hill
2010
Beaumont Hospital
2010
Hospital Clínico Universitario de Valencia
2010
Universitat de València
2010
Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which metastatic sites will be affected.Patients with cancer diagnosed between 1986 1992 archival tissue were included. Subtypes defined as luminal A, B, luminal/human epidermal growth factor receptor 2 (HER2), HER2 enriched, basal-like, triple negative (TN) nonbasal. Distant classified brain, liver, lung, bone, distant nodal, pleural/peritoneal, other. Cumulative incidence curves...
Purpose Adjuvant! ( www.adjuvantonline.com ) is a web-based tool that predicts 10-year breast cancer outcomes with and without adjuvant systemic therapy, but it has not been independently validated. Methods Using the British Columbia Breast Cancer Outcomes Unit (BCOU) database, demographic, pathologic, staging, treatment data on 4,083 women diagnosed between 1989 1993 in T1-2, N0-1, M0 were abstracted entered into to calculate predicted overall survival (OS), cancer–specific (BCSS),...
Abstract BACKGROUND. Over the past decade, a number of new therapeutic agents have become available in treatment metastatic breast cancer (MBC). This study characterized use and assessed impact on survival population‐based access to for MBC. METHODS. The dates release British Columbia 7 systemic MBC during 1990s were used construct 4 time cohorts. All patients with first diagnosis distant metastases each cohorts identified characterized, their was compared. Cox proportional regression...
Purpose To determine if time to start of adjuvant chemotherapy after curative surgery influences survival in early-stage breast cancer. Patients and Methods A retrospective review was conducted 2,594 patients receiving for stage I II cancer between 1989 1998 at the British Columbia Cancer Agency. Relapse-free (RFS) overall (OS) were compared among grouped by from definitive (≤ 4 weeks, > 8 12 >12 24 weeks). Results RFS OS similar women starting up weeks surgery. hazard ratio...
Purpose Human epidermal growth factor receptor 2 gene (HER2) is associated with a poorer outcome in node-positive breast cancer, but the results are conflicting node-negative disease. This study assessed prognostic impact of HER2 overexpression/amplification large series cancers. Patients and Methods A tissue microarray (TMA) was constructed consisting 4,444 invasive cancers diagnosed British Columbia from 1986 to 1992. Within this series, 2,026 patients were node negative, whom 70% did not...
Estrogen receptor (ER) expression predicts improved breast cancer-specific survival and reduced risk of recurrence is targeted in cancer therapy. A high-quality antibody to identify ER-positive patients plays an important role clinical decision making for women with cancer. This study evaluates immunohistochemistry using two anti-ER antibodies, a new rabbit monoclonal (SP1) the mouse (1D5), relation biochemical ER assay results data on adjuvant systemic therapy.A population-based tissue...
Purpose To determine whether the patterns of relapse according to estrogen receptor (ER) and human epidermal growth factor 2 (HER2) status changed in contemporary era. Patients Methods Female patients referred British Columbia Cancer Agency with biopsy-proven stage I III breast cancer (BC), diagnosed between 1986 1992 (cohort 1 [C1]) mid-2004 2008 [C2]), known ER HER2 were eligible. Data prospectively collected. C2 matched C1 for stage, grade, status. The primary end point was hazard rate...
BACKGROUND Adjuvant chemotherapy (AC) is frequently considered in patients with stage II colon cancer who are to be at high risk. However, the authors' knowledge, survival benefits associated AC these remain largely unproven. In current study, authors sought examine use of AJCC and compare impact on outcomes high‐risk versus low‐risk disease a population‐based setting. METHODS Patients were evaluated 1 5 regional centers British Columbia from 1999 2008 analyzed. Kaplan‐Meier Cox regression...
Abstract Due to differences in natural history and therapy, clinical trials of patients with advanced pancreatic cancer have recently been subdivided into unresectable locally ( LAPC ) metastatic disease. We aimed evaluate prognostic factors who were treated first‐line chemotherapy describe patterns disease progression. Patients initiated palliative chemotherapy, 2001–2011 at the BC Cancer Agency included. A retrospective chart review was conducted identify clinicopathologic variables,...
To discuss the absolute benefits from adjuvant systemic therapy knowledge of long-term outcomes and baseline risks relapse disease-specific survival are required. We assessed 10-year in a population-based cohort node-negative (N-) lymphovascular negative (LV-) early breast cancers diagnosed 1989 to 1991 who did not receive therapy.One thousand one hundred eighty-seven cases pT(1-2)N(0) LV- with median follow-up 10.4 years were reviewed. Kaplan-Meier curves for free (RFS), cancer-specific...
The objective of the study was to evaluate association between number lymph nodes removed at axillary dissection and recurrence survival for patients with node-negative invasive breast cancer.Subjects were 2,278 women pathologically cancer, diagnosed from 1989 1993 in British Columbia, Canada. Women aged > or = 90 years, pure in-situ, bilateral cancer T4, N1, N2, M1 stage, who had radiation excluded. Two groups defined analysis: no systemic therapy (n 1,468) 810). Median follow-up 7.5 years....
Purpose To determine if mastectomy (Mx) use, chemotherapy (CT) intensity, or treatment sequence of CT, radiation therapy (RT), and Mx have improved outcome for inflammatory breast cancer (IBC). Patients Methods A retrospective analysis 485 patients with IBC diagnosed in British Columbia between 1980 2000 analyzed locoregional relapse-free survival (LRFS) cancer–specific (BCSS) by intent received. Curative was defined as delivery more than four cycles anthracycline-based CT plus RT without...
To determine the interval from breast-conserving surgery (BCS) to radiation therapy (RT) that affects local control or survival.The 10-year Kaplan-Meier (KM) recurrence-free survival (LRFS), distant (DRFS), and breast cancer-specific (BCSS) were computed for 6,428 women who had T1 2, N0 1, M0 cancer was diagnosed in British Columbia between 1989 2003, treated with BCS RT without chemotherapy. Intervals grouped by weeks as follows: < = 4 (n 83), greater than 8 2,288; reference group); 12...
Breast/chest wall irradiation (RT) increases risk of cardiovascular death. International Quantitative Analysis Normal Tissue Effects in the Clinic (QUANTEC) guidelines state for partial heart a "V25Gy <10% will be associated with <1% probability cardiac mortality" long-term follow-up after RT. We assessed whether women treated breast/chest RT 10-years ago who died disease (CVD) violated QUANTEC guidelines.A population-based database identified all deaths early-stage breast cancer <80 years,...
Prior data about the influence of age at diagnosis breast cancer on patient outcomes and survival has been conflicting. Using Breast Cancer Outcomes Unit database BC Cancer, this retrospective population-based study identified a cohort 24,469 patients diagnosed with invasive between 2005 2014. Median follow-up was 11.5 years. We analyzed clinical pathological features treatment specific variables compared across following cohorts: <35, 35-39, 40-49, 50-59, 60-69, 70-79, 80 years older....